This means that the current basic research does not include the evaluation of the combined effects of Tα1 and radiotherapy, CCRT, targeted therapy, and immunotherapy, and it is necessary to improve these preclinical models to provide theoretical support for the combined application of Tα1 and real-world clinical treatment of LC. The gene discussed is TAAR1; the disease is laryngotracheoesophageal cleft.